DESTINY-Breast03 Phase 3 Study Results
Results From the Phase 1/2 Study of Patritumab Deruxtecan, a
HER3-Directed Antibody-Drug Conjugate (ADC), in Patients With
HER3-Expressing Metastatic Breast Cancer
lan E. Krop, 1 Norikazu Masuda,2 Toru Mukohara,3 Shunji Takahashi,4 Takahiro Nakayama,5 Kenichi Inoue,6
Hiroji Iwata, 7 Tatsuya Toyama,8 Yutaka Yamamoto,9 Damien Hansra, 10 Masato Takahashi, 11 Akihiko Osaki, 12
Kumiko Koyama, 13 Tatsuya Inoue, 14 Takatoshi Yonekura, 13 Joseph Mostillo, 15 Shoichi Ohwada, 13 Yoshimi
Tanaka, 13 David Sternberg, 15
Kan Yonemori 16
1 Yale University, Hartford, CT; 2 Nagoya University Graduate School of Medicine, Nagoya, Japan; 3 National Cancer Center Hospital East,
Kashiwa, Japan; 4 The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; 5 Osaka International Cancer
Institute, Osaka, Japan; 6 Saitama Cancer Center, Saitama Japan; 7 Aichi Cancer Center Hospital, Nagoya, Japan; 8 Nagoya City University,
Nagoya, Japan; 9 Kumamoto University Hospital, Kumamoto, Japan; 10 Piedmont Physicians Medical Oncology, Fayetteville, GA; 11
National Hospital Organization, Hokkaido Cancer Center, Sapporo, Japan; 12 Saitama Medical University International Medical Center;
Hidaka, Japan; 13 Daiichi Sankyo Co., Ltd., Tokyo, Japan; 14 Daiichi Sankyo RD Novare Co., Ltd., Edogawa-Ku, Japan; 15 Daiichi Sankyo, Inc.,
Basking Ridge, NJ; 16 National Cancer Center Hospital, Tokyo, Japan
ASCO 2022 #1002 Oral
On behalf of the investigators
82
22
Daiichi-SankyoView entire presentation